Replimune Group (NASDAQ:REPL) Trading 8.2% Higher – Here’s What Happened

Replimune Group, Inc. (NASDAQ:REPL)’s share price rose 8.2% on Friday . The stock traded as high as $13.03 and last traded at $12.99. Approximately 742,437 shares changed hands during mid-day trading, a decline of 29% from the average daily volume of 1,046,092 shares. The stock had previously closed at $12.01.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Jefferies Financial Group raised their target price on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. HC Wainwright restated a “buy” rating and set a $17.00 price objective on shares of Replimune Group in a research report on Friday, November 22nd. JPMorgan Chase & Co. upped their target price on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Finally, Roth Mkm began coverage on shares of Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Replimune Group has an average rating of “Buy” and a consensus price target of $17.29.

Replimune Group Stock Performance

The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. The stock has a fifty day simple moving average of $12.25 and a two-hundred day simple moving average of $10.73. The firm has a market capitalization of $854.53 million, a P/E ratio of -4.10 and a beta of 1.26.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.07. On average, research analysts predict that Replimune Group, Inc. will post -2.91 EPS for the current year.

Insider Buying and Selling at Replimune Group

In related news, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the sale, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at $2,509,013.88. The trade was a 4.72 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

A number of large investors have recently modified their holdings of the company. Nisa Investment Advisors LLC raised its holdings in Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after buying an additional 4,946 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Replimune Group by 10.7% during the second quarter. Bank of New York Mellon Corp now owns 180,226 shares of the company’s stock worth $1,622,000 after acquiring an additional 17,471 shares in the last quarter. Rhumbline Advisers raised its holdings in shares of Replimune Group by 7.2% in the 2nd quarter. Rhumbline Advisers now owns 84,923 shares of the company’s stock worth $764,000 after acquiring an additional 5,732 shares during the last quarter. TD Asset Management Inc lifted its position in Replimune Group by 4.6% in the 2nd quarter. TD Asset Management Inc now owns 249,940 shares of the company’s stock valued at $2,249,000 after acquiring an additional 11,094 shares in the last quarter. Finally, Arizona State Retirement System acquired a new position in Replimune Group during the 2nd quarter valued at about $108,000. 92.53% of the stock is currently owned by institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.